Menu Search
Equities

Telix Pharmaceuticals Ltd

TLX1N:MEX

Telix Pharmaceuticals Ltd

Actions
  • Price (MXN)138.77
  • Today's Change0.00 / 0.00%
  • Shares traded6.09k
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Apr 16 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Telix Pharmaceuticals Limited is an Australia-based is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. It operates under four business units: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech), and Telix Manufacturing Solutions (TMS). Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx.

  • Revenue in AUD (TTM)645.68m
  • Net income in AUD49.19m
  • Incorporated2017
  • Employees234.00
  • Location
    Telix Pharmaceuticals LtdSuite 401 55 Flemington RoadNorth MelbourneMELBOURNE 3051AustraliaAUS
  • Websitehttps://telixpharma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		TLX:ASX since
announced		Transaction
value
RLS (USA) IncAnnounced22 Sep 202422 Sep 2024Announced2.22%250.00m
ARTMS IncDeal completed04 Mar 202404 Mar 2024Deal completed74.02%82.00m
IsoTherapeutics Group LLCDeal completed27 Feb 202427 Feb 2024Deal completed89.42%12.90m
Data delayed at least 20 minutes, as of Sep 26 2024 07:10 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.